I am an experienced cancer researcher with over eight years of expertise in oncology-focused drug discovery, combining molecular, cellular, and structural biology to uncover therapeutic mechanisms and accelerate drug development. My doctoral research at the City University of New York identified EGR1 as a key mediator of Riluzole-induced apoptosis in osteosarcoma through the YAP/p73-Bax axis, integrating high-throughput screening, fluorescence microscopy, and ChIP-qPCR. Trained in advanced structural biology, I optimized over 200 protein crystals for fragment-based screening, performed X-ray crystallography at the Diamond Light Source, and collaborated with Atomwise on AI-driven drug discovery work was published in Nature Scientific Reports. My earlier computational study on HIV reverse transcriptase resistance, published in the Journal of Molecular Graphics, reflects my ability to bridge computational modeling with experimental biology. Skilled in protein crystallography, structure-based design, biophysical assays, and in vitro/in vivo cancer models, I bring a multidisciplinary approach to studying protein–ligand interactions and validating small-molecule inhibitors. Recognized for scientific rigor, cross-functional collaboration, and problem-solving in fast-paced environments, I am driven by a passion for translating molecular insights into targeted and effective cancer therapeutics.